California-based AI-drug discovery company Deepcell has raised USD 73 million in a Series B funding round led by Koch Disruptive Technologies, with participation from various other new and existing investors. This brings the company’s total funds raised to date to USD 98 million.
The proceeds will be injected into the company’s growth efforts including the development and commercialization of its AI-powered computational platform and the expanding of its team.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.